Kanishk Luhach

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• PDE3 inhibition by cilostazol attenuated developmental hyperserotonemia induced behavioural and biochemical deficits in a rat model of autism spectrum disorder
  Research in Autism Spectrum Disorders 2022 DOI: 10.1016/J.RASD.2022.102052
  +Save
• Vinpocetine ameliorates developmental hyperserotonemia induced behavioral and biochemical changes: role of neuronal function, inflammation, and oxidative stress
  Acta Neurobiologiae Experimentalis 2022 DOI: 10.55782/ANE-2022-004
  +Save
• Vinpocetine, a PDE1 modulator, regulates markers of cerebral health, inflammation, and oxidative stress in a rat model of prenatal alcohol-induced experimental attention deficit hyperactivity disorder
  Alcohol 2022 DOI: 10.1016/J.ALCOHOL.2022.08.005
  +Save
• Attenuation of neurobehavioural abnormalities by papaverine in prenatal valproic acid rat model of ASD
  European Journal of Pharmacology 2021 DOI: 10.1016/j.ejphar.2020.173663
  +Save
• Cilostazol attenuated prenatal valproic acid-induced behavioural and biochemical deficits in a rat model of autism spectrum disorder
  Journal of Pharmacy and Pharmacology 2021 DOI: 10.1093/JPP/RGAB115
  +Save
• Effect of papaverine on developmental hyperserotonemia induced autism spectrum disorder related behavioural phenotypes by altering markers of neuronal function, inflammation, and oxidative stress in rats
  Clinical and Experimental Pharmacology and Physiology 2021 DOI: 10.1111/1440-1681.13459
  +Save
• Vinpocetine amended prenatal valproic acid induced features of ASD possibly by altering markers of neuronal function, inflammation, and oxidative stress
  Autism Research 2021 DOI: 10.1002/AUR.2597
  +Save